9 results on '"Sivanand, Sharanya"'
Search Results
2. Spatiotemporal Control of Acetyl-CoA Metabolism in Chromatin Regulation.
- Author
-
Sivanand, Sharanya, Viney, Isabella, and Wellen, Kathryn E.
- Subjects
- *
METABOLITES , *CHROMATIN , *GENETIC regulation , *HISTONE acetylation , *ENZYMES - Abstract
The epigenome is sensitive to the availability of metabolites that serve as substrates of chromatin-modifying enzymes. Links between acetyl-CoA metabolism, histone acetylation, and gene regulation have been documented, although how specificity in gene regulation is achieved by a metabolite has been challenging to answer. Recent studies suggest that acetyl-CoA metabolism is tightly regulated both spatially and temporally to elicit responses to nutrient availability and signaling cues. Here we discuss evidence that acetyl-CoA production is differentially regulated in the nucleus and cytosol of mammalian cells. Recent findings indicate that acetyl-CoA availability for site-specific histone acetylation is influenced through post-translational modification of acetyl-CoA-producing enzymes, as well as through dynamic regulation of the nuclear localization and chromatin recruitment of these enzymes. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
3. Molecular biology: Salvaging the genome.
- Author
-
Sivanand, Sharanya and Wellen, Kathryn E.
- Subjects
- *
CYTIDINE deaminase , *CANCER treatment , *NUCLEOTIDES , *DNA repair , *GENOMES , *ENZYMES , *EPIGENETICS - Abstract
The article discusses research by Melania Zauri and colleagues, reported in the current issue, on metabolic aspects of carcinogenesis, focusing on the potential for cancer treatments based on the role played by the enzyme cytidine deaminase (CDA) in some tumors. Topics include nucleotide salvage and epigenetically modified nucleotides.
- Published
- 2015
- Full Text
- View/download PDF
4. Nuclear Acetyl-CoA Production by ACLY Promotes Homologous Recombination.
- Author
-
Sivanand, Sharanya, Rhoades, Seth, Jiang, Qinqin, Lee, Joyce V., Benci, Joseph, Zhang, Jingwen, Yuan, Salina, Viney, Isabella, Zhao, Steven, Carrer, Alessandro, Bennett, Michael J., Minn, Andy J., Weljie, Aalim M., Greenberg, Roger A., and Wellen, Kathryn E.
- Subjects
- *
ACETYLCOENZYME A , *GENETIC recombination , *DOUBLE-strand DNA breaks , *DNA repair , *HOMOLOGOUS chromosomes - Abstract
Summary While maintaining the integrity of the genome and sustaining bioenergetics are both fundamental functions of the cell, potential crosstalk between metabolic and DNA repair pathways is poorly understood. Since histone acetylation plays important roles in DNA repair and is sensitive to the availability of acetyl coenzyme A (acetyl-CoA), we investigated a role for metabolic regulation of histone acetylation during the DNA damage response. In this study, we report that nuclear ATP-citrate lyase (ACLY) is phosphorylated at S455 downstream of ataxia telangiectasia mutated (ATM) and AKT following DNA damage. ACLY facilitates histone acetylation at double-strand break (DSB) sites, impairing 53BP1 localization and enabling BRCA1 recruitment and DNA repair by homologous recombination. ACLY phosphorylation and nuclear localization are necessary for its role in promoting BRCA1 recruitment. Upon PARP inhibition, ACLY silencing promotes genomic instability and cell death. Thus, the spatial and temporal control of acetyl-CoA production by ACLY participates in the mechanism of DNA repair pathway choice. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
5. Inhibition of hypoxia-inducible factors limits tumor progression in a mouse model of colorectal cancer.
- Author
-
Shay, Jessica E. S., Imtiyaz, Hongxia Z., Sivanand, Sharanya, Durham, Amy C., Skuli, Nicolas, Hsu, Sarah, Mucaj, Vera, Eisinger-Mathason, T. S. Karin, Krock, Bryan L., Giannoukos, Dionysios N., and Simon, M. Celeste
- Abstract
Hypoxia-inducible factors (HIFs) accumulate in both neoplastic and inflammatory cells within the tumor microenvironment and impact the progression of a variety of diseases, including colorectal cancer. Pharmacological HIF inhibition represents a novel therapeutic strategy for cancer treatment. We show here that acriflavine (ACF), a naturally occurring compound known to repress HIF transcriptional activity, halts the progression of an autochthonous model of established colitis-associated colon cancer (CAC) in immunocompetent mice. ACF treatment resulted in decreased tumor number, size and advancement (based on histopathological scoring) of CAC. Moreover, ACF treatment corresponded with decreased macrophage infiltration and vascularity in colorectal tumors. Importantly, ACF treatment inhibited the hypoxic induction of M-CSFR, as well as the expression of the angiogenic factor (vascular endothelial growth factor), a canonical HIF target, with little to no impact on the Nuclear factor-kappa B pathway in bone marrow-derived macrophages. These effects probably explain the observed in vivo phenotypes. Finally, an allograft tumor model further confirmed that ACF treatment inhibits tumor growth through HIF-dependent mechanisms. These results suggest pharmacological HIF inhibition in multiple cell types, including epithelial and innate immune cells, significantly limits tumor growth and progression. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
6. Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma.
- Author
-
Tram Anh Tran, Hon Sing Leong, Pavia-Jimenez, Andrea, Fedyshyn, Slavic, Juan Yang, Kucejova, Blanka, Sivanand, Sharanya, Spence, Patrick, Xian-Jin Xie, Peña-Llopis, Samuel, Power, Nicholas, and Brugarolas, James
- Subjects
- *
CANCER treatment , *RENAL cell carcinoma , *ENDOTHELIAL cells , *FIBROBLASTS , *NEOVASCULARIZATION , *VASCULAR endothelial growth factors , *PHOSPHORYLATION - Abstract
Antiangiogenic therapies, such as sunitinib, have revolutionized renal cell carcinoma (RCC) treatment. However, a precarious understanding of how resistance emerges and a lack of tractable experimental systems hinder progress. We evaluated the potential of primary RCC cultures (derived from tumors and tumor grafts) to signal to endothelial cells (EC) and fibroblasts in vitro and to stimulate angiogenesis ex vivo in chorioallantoic membrane (CAM) assays. From 65 patients, 27 primary cultures, including several from patients with sunitinib-resistant RCC, were established. RCC cells supported EC survival in coculture assays and induced angiogenesis in CAM assays. RCC-induced EC survival was sensitive to sunitinib in half of the tumors and was refractory in tumors from resistant patients. Sunitinib sensitivity correlated with vascular endothelial growth factor (VEGF) production. RCC induced paracrine extracellular signal-regulated kinase (ERK) activation in EC which was inhibited by sunitinib in sensitive but not in resistant tumors. As determined by fibroblast growth factor receptor substrate 2 (FRS2) phosphorylation in fibroblasts, RCC broadly induced low-level fibroblast growth factor receptor (FGFR) signaling. Whereas ERK activation in EC was uniformly inhibited by combined VEGF/platelet-derived growth factor (PDGF)/FGF receptor inhibitors, paracrine ERK activation in fibroblasts was blocked in only a fraction of tumors. Our data show that RCC activates EC through VEGF-dependent and -independent pathways, that sunitinib sensitivity correlates with VEGF-mediated ERK activation, and that combined inhibition of VEGF/PDGF/FGF receptors is sufficient to inhibit mitogenic signaling in EC but not in fibroblasts. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
7. BAP1 loss defines a new class of renal cell carcinoma.
- Author
-
Peña-Llopis, Samuel, Vega-Rubín-de-Celis, Silvia, Liao, Arnold, Leng, Nan, Pavía-Jiménez, Andrea, Wang, Shanshan, Yamasaki, Toshinari, Zhrebker, Leah, Sivanand, Sharanya, Spence, Patrick, Kinch, Lisa, Hambuch, Tina, Jain, Suneer, Lotan, Yair, Margulis, Vitaly, Sagalowsky, Arthur I, Summerour, Pia Banerji, Kabbani, Wareef, Wong, S W Wendy, and Grishin, Nick
- Subjects
- *
RENAL cell carcinoma , *CARCINOGENESIS , *GENOMES , *NUCLEOTIDE sequence , *TUMOR suppressor genes , *CELL proliferation , *GENE expression , *UBIQUITINATION - Abstract
The molecular pathogenesis of renal cell carcinoma (RCC) is poorly understood. Whole-genome and exome sequencing followed by innovative tumorgraft analyses (to accurately determine mutant allele ratios) identified several putative two-hit tumor suppressor genes, including BAP1. The BAP1 protein, a nuclear deubiquitinase, is inactivated in 15% of clear cell RCCs. BAP1 cofractionates with and binds to HCF-1 in tumorgrafts. Mutations disrupting the HCF-1 binding motif impair BAP1-mediated suppression of cell proliferation but not deubiquitination of monoubiquitinated histone 2A lysine 119 (H2AK119ub1). BAP1 loss sensitizes RCC cells in vitro to genotoxic stress. Notably, mutations in BAP1 and PBRM1 anticorrelate in tumors (P = 3 × 10?5), and combined loss of BAP1 and PBRM1 in a few RCCs was associated with rhabdoid features (q = 0.0007). BAP1 and PBRM1 regulate seemingly different gene expression programs, and BAP1 loss was associated with high tumor grade (q = 0.0005). Our results establish the foundation for an integrated pathological and molecular genetic classification of RCC, paving the way for subtype-specific treatments exploiting genetic vulnerabilities. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
8. FK228 Analogues Induce Fetal Hemoglobin in Human Erythroid Progenitors.
- Author
-
Makala, Levi, Di Maro, Salvatore, Tzu-Fang Lou, Sivanand, Sharanya, Jung-Mo Ahn, and Pace, Betty S.
- Subjects
- *
PROGENITOR cells , *HEMOGLOBINS , *FETAL physiology , *SICKLE cell anemia , *LUCIFERASES , *MOLECULAR models , *MOLECULAR structure - Abstract
Fetal hemoglobin (HbF) improves the clinical severity of sickle cell disease (SCD), therefore, research to identify HbF-inducing agents for treatment purposes is desirable. The focus of our study is to investigate the ability of FK228 analogues to induce HbF using a novel KU812 dual-luciferase reporter system. Molecular modeling studies showed that the structure of twenty FK228 analogues with isosteric substitutions did not disturb the global structure of the molecule. Using the dual-luciferase system, a subgroup of FK228 analogues was shown to be inducers of HbF at nanomolar concentrations. To determine the physiological relevance of these compounds, studies in primary erythroid progenitors confirmed that JMA26 and JMA33 activated HbF synthesis at levels comparable to FK228 with low cellular toxicity. These data support our lead compounds as potential therapeutic agents for further development in the treatment of SCD. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
9. Erratum: BAP1 loss defines a new class of renal cell carcinoma.
- Author
-
Peña-Llopis, Samuel, Vega-Rubín-de-Celis, Silvia, Liao, Arnold, Leng, Nan, Pavía-Jiménez, Andrea, Wang, Shanshan, Yamasaki, Toshinari, Zhrebker, Leah, Sivanand, Sharanya, Spence, Patrick, Kinch, Lisa, Hambuch, Tina, Jain, Suneer, Lotan, Yair, Margulis, Vitaly, Sagalowsky, Arthur I, Summerour, Pia Banerji, Kabbani, Wareef, Wong, S W Wendy, and Grishin, Nick
- Subjects
- *
RENAL cell carcinoma , *CANCER research - Abstract
A correction to the article "BAP1 loss defines a new class of renal cell carcinoma," that was published in a 2012 issue is presented.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.